Objective
To evaluate the consequences of COVID‐19 pandemic restrictions on the postpartum course.
Methods
A retrospective cross‐sectional study compared women who gave birth between March and April 2020 (first wave), between July to September 2020 (second wave), and a matched historical cohort throughout 2017–2019 (groups A, B, and C, respectively). Primary outcomes were postpartum length of stay (LOS), presentations to the emergency department (ED), and readmissions 30 days or longer after discharge. Following Bonferroni correction, p < 0.016 was considered statistically significant.
Results
In total, 3377 women were included: 640, 914, and 1823 in groups A, B, and C, respectively. LOS after birth (both vaginal and cesarean) was shorter in groups A and B compared to the control group (2.28 ± 1.01 and 2.25 ± 0.93 vs 2.55 ± 1.10 days, p < 0.001). Rates of ED presentations 30 days after discharge were higher in groups C and B compared to group A (6.63% and 6.45% vs 3.12%, p = 0.006). Rates of readmissions 30 days after discharge were 0.78%, 1.42%, and 1.09% (groups A, B, and C, respectively), demonstrating no statistical difference (p = 0.408).
Conclusion
During the COVID‐19 pandemic, there was a reduction or no change in rates of ED presentations and readmissions, despite the shortened LOS after delivery. A shift in policy regarding the postpartum LOS could be considered.
High mRNA and protein levels of PDE1A were observed in EOCs compared to borderline, benign and normal nonadjacent ovarian epithelial tissues (p < 0.001). Also, high expression of PDE1A was significantly associated with serous (p = 0.023), high grade (p = 0.012), advanced stage FIGO stage (p < 0.001), and resistance to platinum based chemotherapy (p < 0.001) EOCs. Importantly, high expression level of PDE1A was indicated as a prognosis predictive biomarker by Cox mulrivariate analysis. Specifically, we observed that PDE1Apromoted G2/M transition by regulating cyclin B1 trascription. Conclusion Taken together, our findings suggested that PDEA1A is a promosing biomarker for prediction of progosnosis and resistance to platinum based chemotherapy in EOC patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.